Eleclazine

Phase 2Small molecule

Gilead

Eleclazine is one of 43 small molecule programs targeting Ventricular arrhythmia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ventricular ArrhythmiaActive, not recruiting

Hypertrophic CardiomyopathyActive, not recruiting

Ventricular ArrhythmiaPhase 2

Active, not recruiting

Hypertrophic CardiomyopathyPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Hypertrophic Cardiomyopathy

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

2 2

Adenocard

Astellas

Approved

1 3

Lexiscan

Astellas

Approved

1 4

Zebeta

Teva

Approved

1 5

Bayer Aspirin

Bayer

Approved

—6

Cardizem

BBausch Health Americas, Inc.

Approved

2 7

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

19 8

Calan

VVal Adams

Approved

1 9

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Approved

1 10

Xarelto

WWim Janssens

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Impaired Renal Function1 trial

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Completed· Gilead logo

Gilead·Phase 1·NCT02441829·55 enrolled

Ventricular arrhythmia1 trial

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

Completed· Gilead logo

Gilead·Phase 2·NCT02104583·313 enrolled

Hypertrophic Cardiomyopathy1 trial

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Terminated· Gilead logo

Gilead·Phase 2/3·NCT02291237·172 enrolled

ART1 trial

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

Completed· Gilead logo

Gilead·Phase 1·NCT02365506·13 enrolled

Long QT Syndrome1 trial

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Terminated· Gilead logo

Gilead·Phase 3·NCT02300558·41 enrolled

1 more indication

Hepatic Function1 trial

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Completed· Gilead logo

Gilead·Phase 1·NCT02412098·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Eleclazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eleclazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eleclazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Gilead

Eleclazine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Impaired Renal Function1 trial

Ventricular arrhythmia1 trial

Hypertrophic Cardiomyopathy1 trial

ART1 trial

Long QT Syndrome1 trial

Hepatic Function1 trial

References

Drug Info

Quick Facts

Related News